Exchange of Thailand In accordance with the resolution of the Board of Directors Meeting of Inter Pharma Public Company Limited ("the Company") No. 4/2020, held on 8th June 2020, has approved the Company to
million decreased by Baht 303.39 million, or 16.42% from the previous year, mainly from the decrease of branches from 106 branches to 97 branches. 2. The Company’ s cost of goods sold in the year 2018 were
increased from THB 82.00 million to THB 133.61 million or increased THB 51.61 million or 62.94% because film production and films rights distribution generated more revenue than last year. Cost and expense of
compared with Q3 year 2017. Cost of Sales for Q3 year 2018 and Q3 year 2017 was 355.25 million baht and 331.79 million baht, respectively. It increased 23.45 million baht or 7.07% when compared with Q3 year
price that decreased due to the global economic slowdown as a result of trade protection measures between China and the United States. - The company has cost of sales of 616.03 million baht or 84.14% of
Shareholders No. 1/2017 which was held on 30 August 2017 with the disapproval resolution for the Debt to Equity Conversion Scheme, which impacted the Company’s ability to repay the debts in the amount of USD
สารสนเทศข่าว มติ BOD 5-60 Final 20171126 En No. NDR013/2017 Subject Resolution of the Board of Directors’ Meeting To President The Stock Exchange of Thailand Enclosure 1. Information Memorandum on 2
Board of Directors of Company approved this transaction, there was the resolution on Non-proportional capital increase in subsidiary arising from conversion of debt to equity which the highest value is
Thailand In reference to the Board of Directors' meeting of Safari World Public Company Limited (the "Company") No. 6/2561 on May 25, 2018, the Board of Directors had a resolution for the Company to enter
has considered additional facts and the study results of the changed cost structure. It was found that the continuation of the project on the basis of the existing guidelines could result in offering no